Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A

Monday, December 1, 2014

Source: Baxter International

Baxter International Inc. announced that the company has submitted a biologics license application to the United States Food and Drug Administration for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII treatment for hemophilia A based on ADVATE Factor.

View All News »